statistiche ricercatore

Nazione	#
US - Stati Uniti d'America	362
RU - Federazione Russa	341
SG - Singapore	154
BR - Brasile	76
CN - Cina	54
HK - Hong Kong	35
IE - Irlanda	35
SE - Svezia	27
VN - Vietnam	23
IT - Italia	18
DE - Germania	13
GB - Regno Unito	13
FR - Francia	11
FI - Finlandia	9
IN - India	8
BD - Bangladesh	7
NL - Olanda	7
PK - Pakistan	7
CA - Canada	6
AR - Argentina	5
ZA - Sudafrica	5
AL - Albania	3
AT - Austria	3
BE - Belgio	3
BO - Bolivia	3
DZ - Algeria	3
KG - Kirghizistan	3
MX - Messico	3
PE - Perù	3
PH - Filippine	3
PL - Polonia	3
TR - Turchia	3
CZ - Repubblica Ceca	2
JO - Giordania	2
MA - Marocco	2
PY - Paraguay	2
AE - Emirati Arabi Uniti	1
CL - Cile	1
CR - Costa Rica	1
CY - Cipro	1
EC - Ecuador	1
EG - Egitto	1
ES - Italia	1
ET - Etiopia	1
GT - Guatemala	1
ID - Indonesia	1
IL - Israele	1
IQ - Iraq	1
IR - Iran	1
JP - Giappone	1
KZ - Kazakistan	1
LA - Repubblica Popolare Democratica del Laos	1
LT - Lituania	1
LU - Lussemburgo	1
NP - Nepal	1
NZ - Nuova Zelanda	1
PA - Panama	1
RO - Romania	1
SA - Arabia Saudita	1
SK - Slovacchia (Repubblica Slovacca)	1
Totale	1.281

Nome	#
Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors	192
Cancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis	153
Assessment of enthesis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound	143
Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study	142
Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data	96
Efficacy of cyclophosphamide in treating connective tissue disease-related interstitial lung diseases	88
The effect of drugs used in rheumatology for treating SARS-CoV2 infection	88
Concerns about the safety of anti-TNF agents when treating rheumatic diseases	85
Toxicological considerations in the treatment of axial spondylo-arthritis	74
The rheumatology drugs for COVID-19 management: Which and when?	65
Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications	62
Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs?	60
Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides?	55
Totale	1.303

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	4	0	0	0	0	0	0	0	0	0	0	4	0
2021/2022	36	1	2	0	3	1	0	2	0	0	7	0	20
2022/2023	115	9	12	7	15	6	12	1	4	47	1	1	0
2023/2024	49	3	2	8	5	4	23	0	2	0	1	0	1
2024/2025	298	10	5	3	19	7	16	16	49	58	29	40	46
2025/2026	765	32	64	41	52	75	173	95	109	83	41	0	0
Totale													1.303